ÄϹ¬NG28¼¯ÍÅ

nyba
ѧ¿Æ½¨Éè
Ê×Ò³ > ѧ¿Æ½¨Éè > ÕýÎÄ
ѧ¿Æ½¨Éè
ѧ¿Æ½¨Éè

ÄϹ¬NG28¼¯ÍÅÁ¥ÊôҽԺͷ¾±²¿Ö×Áöר¿ÆÍŶÓÊ×´ÎÁÁÏà¹ú¼Ê¶¥¼¶Ö×ÁöѧÄê»áÎę̀

ȪԴ£º ʱ¼ä£º2024-06-11µã»÷£º

ÃÀ¹ú¶«²¿Ê±¼ä5ÔÂ31ÈÕ-6ÔÂ4ÈÕ£¬£¬2024ÄêµÚ60½ìÃÀ¹úÁÙ´²Ö×Áöѧ»á£¨ASCO£©Äê»áÔÚÃÀ¹úÖ¥¼Ó¸ç¾ÙÐС£¡£¡£ASCOÄê»á»ã¾ÛÈ«ÇòÁÙ´²Ö×ÁöѧÑо¿µÄ¾«Ó¢£¬£¬ÊÇ×î¾ßÓ°ÏìÁ¦µÄÖ×ÁöѧÊõ¾Û»á£¬£¬±»ÓþΪ¹ú¼ÊÖ×Áöѧ¡°°Â˹¿¨Ê¢µä¡±¡£¡£¡£ÄϹ¬NG28¼¯ÍŲ©Ê¿ºóÏàÖúµ¼Ê¦¡¢¡¢ÄϹ¬NG28¼¯ÍÅÁ¥ÊôҽԺͷ¾±²¿Ö×Áöר¿Æ¸±Ö÷ÈΣ¨Ö÷³ÖÊÂÇ飩ÂÞº£ÇåÍŶÓÒ»Ïî¿ÆÑÐЧ¹û±»´ó»áÎüÊÕ£¬£¬²¢ÒÔ±Ú±¨ÐÎʽչʾ£¨Poster Session£©Óë¹ú¼ÊÙÉÐоÙÐн»Á÷¡£¡£¡£Í¬Ê±£¬£¬¸ÃÏîЧ¹ûÒѱ»TOPÆÚ¿¯JCO£¨Journal of Clinical Oncology£©£¨IF=45.3£©ÒÔÕªÒªÐÎʽÊÕ¼£¬£¬ÕâÊÇÁ¥ÊôÒ½ÔºÊ×´ÎÒÔ±Ú±¨Õ¹Ê¾µÄÐÎʽÏÖ³¡¼ÓÈëASCOÄê»á½»Á÷µÄÑо¿ÏîÄ¿£¬£¬Ò²ÊÇÔÁÎ÷µØÇøÒ½ÔºµÄ¿ÆÑÐÁ¢Òì¡£¡£¡£

¸ÃÑо¿ÏîĿΪ¡¶ÌæÀ×ÀûÖéµ¥¿¹ÁªºÏnab-TPи¨Öú»¯ÁÆÐò¹áÌæÀ×ÀûÖéµ¥¿¹ÁªÌõÔ¼²½·Å»¯ÁƱÈÕÕnab-TPи¨Öú»¯ÁÆÐò¹áͬ²½·Å»¯ÁÆÖÎÁƾֲ¿ÍíÆÚ±ÇÑʰ©µÄ»ØÊ×ÐÔÑо¿¡·¡£¡£¡£Ñо¿Åä¾°£ºÐ¸¨Öú»¯ÁÆÐò¹áͬÆÚ»¯·ÅÁÆ(CCRT)±»ÁÐΪ¾Ö²¿ÍíÆÚ±ÇÑʰ©(LA-NPC)µÄ±ê×¼ÖÎÁÆÒªÁ죬£¬Ö»¹Üи¨Öú»¯ÁÆÐò¹áCCRTÌá¸ßÁ˱ÇÑʰ©»¼ÕßµÄÉúÑÄÂÊ£¬£¬µ«ÈÔÓÐÔ¼15-25%µÄ»¼Õß·ºÆðÁËÖÎÁÆÊ§°Ü¡£¡£¡£Òò´Ë£¬£¬ÓÐÐëÒªÔÚи¨Öú»¯ÁÆÐò¹áCCRTµÄ»ù´¡ÉϽøÒ»²½Ì½Ë÷¸ßЧµÍ¶¾µÄÖÎÁÆÒªÁì¡£¡£¡£

ÂÞº£ÇåÖ÷ÈÎҽʦÍŶӵÄÑо¿»ØÊ×ÐÔ½ÏÁ¿ÁËÌæÀ×ÀûÖéµ¥¿¹ÁªºÏи¨Öú»¯ÁƺÍCCRTÓë±ê×¼ÖÎÁƵÄÁÆÐ§ÓëÇå¾²ÐÔ¡£¡£¡£Ñо¿Ð§¹ûÏÔʾ£¬£¬ÓëͨÀýÖÎÁÆÏà±È£¬£¬ÌæÀ×ÀûÖéµ¥¿¹ÁªºÏи¨Öú»¯ÁƺÍCCRTÖÎÁƾÖÍíÆÚ±ÇÑʰ©»¼ÕßµÄÁÆÐ§ÁîÈ˹ÄÎ裬£¬Ð¸¨Öú»¯ÁƺóµÄCRÂÊÌáÉýÁË24.4 %£¨37.2 % vs 12.8 %,P= 0.01£©£¬£¬ËõÁöÏÔ×Å£¬£¬3ÄêÎÞÏ£ÍûÉúÑÄÂÊÑÓÉìÁË13.75 % (93.75 % vs 80.0 %,P= 0.04, HR = 0.31£©£»£»ÇÒÄÍÊÜÐÔÓÅÒ죬£¬¿ÉΪ¾ÖÍíÆÚ±ÇÑʰ©»¼Õß´øÀ´¸ü¶àÉúÑÄ»ñÒæºÍÖÎÁÆÑ¡Ôñ¡£¡£¡£¸ÃÑо¿µÚÒ»×÷ÕßΪÄϹ¬NG28¼¯ÍÅ2021¼¶Ö×Áöѧ˶ʿÑо¿ÉúºÎ¼Ñçù£¬£¬Í¨Ñ¶×÷ÕßΪÂÞº£ÇåÖ÷ÈΡ£¡£¡£

´Ë´ÎÈëÑ¡ASCOÄê»á±Ú±¨»·½Ú£¬£¬ÔÚ¹ú¼Ê¶¥¼¶Ö×ÁöѧÄê»áÎę̀ÉÏÕÃÏÔÁËÄϹ¬NG28¼¯ÍÅÔÚÁÙ´²Ö×Áö¿ÆÑÐÁìÓòµÄÁ¢ÒìʵÁ¦¡£¡£¡£¾ÝϤ£¬£¬ÕâÊÇÄϹ¬NG28¼¯ÍÅÖ×ÁöѧÑо¿ÉúÊ×´ÎÔÚÃÀ¹úÁÙ´²Ö×ÁöѧÄê»áASCOºÍ¶¥¼¶ÔÓÖ¾JCOÉϽÒÏþѧÊõ¿´·¨¡£¡£¡££¨ÎÄ/µËͯԪ¡¢¡¢ÂÞº£Çå  Í¼/ÂÞº£Çå  ÉóºË/²Ì¶¨±ò ¸´ºË/ÖÜÔ² Éó·¢/Åá½ðÌΣ©

83AD8A5566D3A9C14EA42783EE3_D0B1941D_96B0

9B82AC450BB247EE9F91CBD7EF8_42738B50_E099B

5C8BC86FAC0C6EA76065349E21E_AA8373E8_113B3

¡¾¹Ø±Õ¡¿

×îÐÂÐÂÎÅ
¡¾ÍøÕ¾µØÍ¼¡¿